Replies to post #35008 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Nope, I'm saying that they both have trials against the same (current/then) standard of care control -- Stupps protocol. Novocure costs 252,000 per year, has more side effects than DCVax-L and DCVax-L will likely swamp Novocure's results against the (current/then) existing SOC (aka: Stupps protocol). (Even in the very unlikely case of an approximate tie with Novocure's earlier results, DCVax-L can also be approved because of superior safety and cost). The FDA does not have to postpone a decision for Novocure.